Lenalidomid Aristo

lenalidomide, the active ingredient in Lenalidomid Aristo, is a Immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients, including those with relapsed or refractory disease, and is administered under specialist supervision.

GNH USA supplies Lenalidomid Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance.

Lenalidomide is used in hematologic malignancies and bone‑marrow failure disorders, targeting abnormal plasma cells and dysplastic clones. - Multiple myeloma: improves progression‑free survival and response rates in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Relapsed or refractory multiple myeloma: enhances overall response when combined with other agents.

Lenalidomide is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Diarrhea - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia - Secondary primary malignancies

When prescribing lenalidomide, clinicians should observe several safety measures to minimize risks. - Monitor blood counts regularly: detect neutropenia, anemia, thrombocytopenia. - Assess renal function before initiation: adjust dosing if impaired. - Counsel women of childbearing potential: risk of fetal harm; use effective contraception. - Avoid concomitant teratogenic drugs: increased risk of birth defects. - Evaluate thromboembolic risk: consider prophylactic anticoagulation when indicated. - Store at room temperature: keep in original container, protect from moisture.

Lenalidomide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise lenalidomide exposure. - Immunosuppressants (e.g., cyclosporine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): lower drug levels. - NSAIDs (e.g., ibuprofen): heightened gastrointestinal toxicity. - Live vaccines: diminished immune response.